Inflammatory bowel disease (IBD) is increasing around the world. In 1990, around 3.7 million people had the condition; by 2017, that number had increased to 6.8 million. Nearly half of IBD patients dont respond to current treatments, and even for the lucky ones therapeutic efficacy can wane over time. As a result, there is an urgent need to develop a new generation of IBD therapies.

Unfortunately, ineffective drug development models are hampering the search for more effective treatments. Conventional two-dimensional (2D) cell models only capture bits and pieces of IBDs complexity, and many three-dimensional (3D) culture models like organoids fall short because they lack critical biological features, such as vasculature and biomechanical forces.

Animal models have their own drawbacks, as their immune systems fail to replicate many of the mechanisms associated with human immunity.

If you look at the physiology of cardiac muscle or neurons between humans and mice, theyre fairly similar, said Christopher Carman, PhD, director of Immunology at Emulate. Theres more divergence in immunology, and it can be really challenging to extract meaningful insights around immune-system-driven mechanisms. Thats why so many therapeutics fail.

To remedy this, Emulate has developed a Colon Intestine-Chip that combines primary human tissue, vasculature, mechanical forces, and (most importantly) immune cell recruitment to recapitulate the biology that drives IBD.

UNDERSTANDING HOW IBD EVOLVES

IBD begins with an unknown tissue insult, and the body responds by producing inflammatory cytokines and chemokines. In turn, these proteins recruit immune cells to the intestine, inducing further inflammation.

This process generates a cytokine cascade. Two proteins in particular, interferon gamma (IFN) and IL-22, act directly on colon epithelial cells, driving cell death, microvilli loss, and destruction of the tight junctions that guard intestinal permeability.

That is a critical hallmark of this disease, said Carman. As a result, intestinal material, including bacteria and bacterial products, leak into the interstitial space, driving even more inflammation.

MAKING THE COLON INTESTINE-CHIP

The Emulate Colon Intestine-Chip was designed to precisely recapitulate this inflammatory cascade.

This advanced, in vitro intestine model incorporates primary human biopsy tissue cultured into organoids. Critically, the cells retain their stemness, meaning they replicate the stem cell niches that are constantly regenerating in human intestines.

After the organoids are dissociated, they are seeded in the top channel of the Organ-Chip. The bottom channel contains primary human intestine-derived microvascular endothelial cells, which are in close proximity to the epithelial cells, as they would be in vivo. The channels are separated by a porous membrane coated with tissue-relevant extracellular matrix proteins.

From there, mechanical forces on the chipphysiologic flow and cyclic stretchreplicate intestinal peristalsis, which improves cell morphology and functionality while supporting more accurate gene expression.

As a result, epithelial tissues respond to microvasculature cues, and the epithelial cells differentiate into all three major epithelial types at the appropriate ratios.

With this, the Emulate Colon Intestine-Chip is able to model IBD from the initial insult to the cytokine cascade, demonstrating along the way selective immune cell recruitment, cell death, and tight junction loss. This model can be applied to study inflammation-specific immune recruitment from vasculature into epithelial tissue and subsequent downstream impacts.

We have shown that this Organ-Chip strongly reflects what we see in primary human tissue, said Carman. It develops proper tight junctions and a strong functional barrier. On the molecular level, we see transcriptional signatures that are highly reflective of primary human tissue.

This model has demonstrated the efficacy of small molecule inhibitors that target IFN and IL-22 signaling pathways, meaning researchers can use it to validate clinically relevant drug candidates designed to prevent barrier dysfunction.

SELECTIVELY GENERATING INFLAMMATION

One of the Organ-Chips most important abilities is the selective recruitment of immune cells. This selectivity comes from tissue-specific adhesion molecules on both endothelial and immune cells, which must be highly specific to bind.

Around 30% of the bodys circulating immune cells are customized for work in the intestines. They have a molecule called 47 integrin that binds to an endothelial molecule called MAdCAM-1, which is preferentially expressed in the colon endothelium and up-regulated in response to inflammatory cues.

One of the major ways the Colon Intestine-Chip replicates IBD biology is by expressing MAdCAM-1 in response to inflammatory stimuli, giving it tremendous relevance for therapeutic discovery.

The 47 integrin/MAdCAM-1 adhesion molecule axis is an important therapeutic target, said Carman. If we can interfere with that adhesion, we can potentially interrupt the inflammatory cascade. And because this mechanism is selective to the gut, any therapeutic that targets these adhesion molecules would be highly specific to the intestinal system.

One drug, AJM300, is in phase three clinical trials right now and is showing promising safety and efficacy, said Carman. We validated that efficacy in our model. We also used the model to study the corticosteroid dexamethasone, which has been a mainstay in IBD treatment for many years. We recently published the data in an application note.

The Colon Intestine-Chip provides a more complete picture of human IBD pathogenesis, delivering a human-relevant platform to test drug efficacy. However, for Emulate, its just the beginning. Inflammation plays a major role in many conditions, and creating models that effectively replicate those pathways will be essential in validating and advancing therapeutic compounds to support better care.

This IBD model is our first foray into inflammation, said Carman. Were planning on developing many variations on this theme to create better tools for a variety of inflammation-driven indications.

For more information on Emulates IBD model, please download Modeling Inflammation-Specific Immune Cell Recruitment in the Colon Intestine-Chip.

Read more from the original source:
Recapitulating Inflammation: How to Use the Colon Intestine-Chip to Study Complex Mechanisms of IBD - Pharmaceutical Executive

Cardiac Stem Cells Comments Off on Recapitulating Inflammation: How to Use the Colon Intestine-Chip to Study Complex Mechanisms of IBD – Pharmaceutical Executive | September 27th, 2022

ONE of the most aggressive types of cancer is looking more beatable thanks to an exciting breakthrough.

Patients with glioblastoma - a fast-growing type of cancer that affects the brain and spinal cord - tend to survive just 15 months from the moment of diagnosis.

1

And currently, few successful long-term treatments are available.

But scientists at the Keck School of Medicine of USC have made a discovery that may offer real hope.

The team found that circadian clock proteins - which control our natural rhythms, like when we wake up and when we fall asleep - could be involved in the growth of glioblastoma tumours.

These proteins may also explain why people often do not remain in remission after cancer treatment, and see their glioblastoma come back.

Keck researchers identified a small molecule drug, called SHP656, that could be used to target those clock proteins and treat the devastating disease.

In the vast majority of patients, the cancer returns. And when it returns, its resistant to chemotherapy and radiation, said Professor Steve Kay at Keck.

Kay and his team believe the disease often returns because of cancer stem cells that spread fast by hijacking the bodys circadian clock mechanisms.

But SHP656 could be used to put a stop to that.

This is a potent molecule thats very exciting to us in terms of its potential for deployment against glioblastoma, said Kay.

Clinical trials are now in motion and the team hopes to begin the next phase in glioblastoma patients within two to three years.

Glioblastomas are grade 4brain tumoursand are a type of glioma, one of the most common types of primary brain tumours.

The cancer begins in the brain and almost never spreads to other parts of the body.

However, its complexity makes it difficult to treat.

There are no known causes of glioblastoma making treatment even trickier.

The first line of treatment is surgery to try and cut the tumour out.

However, it's very difficult to remove the tumour without harming healthy parts of the brain.

Chemotherapy and radiation therapy can be helpful to stop the tumour cells growing and spreading.

But despite the high intensity of the treatment, the cancer usually recurs.

Excerpt from:
New drug could cure aggressive brain cancer stopping tumours in their tracks... - The US Sun

Spinal Cord Stem Cells Comments Off on New drug could cure aggressive brain cancer stopping tumours in their tracks… – The US Sun | September 27th, 2022

A new approach is paving the way for improved stem cell therapies and regenerative applications using cells from pigs. Led by Wan-Ju Li, a SCRMC researcher and associate professor in the Department of Orthopedics and Rehabilitation and the Department of Biomedical Engineering, this new study published in Scientific Reports offers a viable strategy to enhance the generation of induced pluripotent stem cellsfrom large animal cells and provides researchers with insight into the underlying mechanism controlling the reprogramming efficiency of cells. In turn, this approach will allow researchers to reprogram cells more efficiently into iPSCs which can be used to study regenerative therapies aimed at treating everything from osteoarthritis to heart disease.

While this approach can be applied to regenerative therapies targeting any organ or tissue, Li and his Musculoskeletal Biology and Regenerative Medicine Laboratory study cartilage, so he developed the model by deriving iPSCs from the fibroblast cells of three different breeds of miniature pigs including Wisconsin miniature swine, Yucatan miniature swineand Gttingen minipigs. Fibroblast cells are easily obtained for cellular reprogramming and Li is interested in using these cells to efficiently develop cartilage cells that can be used to help patients experiencing osteoarthritis. But, while his goal for the study was specific, the model has wide-reaching implications.

"This model we created can be used for many applications," says Li. "In successfully developing iPSCs from three different breeds of minipigs, we learned we can take somatic skin cells from these pigs that we programmed ourselves into iPSCs and then inject them back into the same animal to treat the disease. Or we can take the cell that carried the disease gene and put that into the culture dish and use that as a disease model to study disease formation."

Li explained that iPSCs can be created from nearly any type of somatic cell, such as skin or blood cells, that are reprogrammed back into an embryonic-like pluripotent cells. These pluripotent stem cells are the bodys master cells and are, therefore, able to become nearly any cell in the body. Harnessing the power of such a cell and being able to grow these versatile cells in the lab is invaluable to medicine as these cells can be used for the regeneration or repair of damaged tissue and in drug testing to see how medication will impact heart, liver, or other cells within the body.

Through this research, Li and his lab have provided researchers with insight into the underlying mechanism controlling the reprogramming efficiency of iPSCs, allowing researchers to harness to power of iPSCs and develop them more efficiently. Specifically, he discovered that the expression level of the switch/sucrose nonfermentable component BAF60A, which is essentially a protein that can remodel the way DNA is packaged, helps to determine the efficiency of iPSC generation. He also noted that the BAF60A is regulated by STAT3, a transcription factor protein that plays a role in cell growth and death. Through this, Li discovered that the efficiency of iPSC generation is based on the expression level of these proteins and that the expression levels vary among pig breeds.

"While we successfully developed iPSCs and programmed iPSCs from the three different strains of pig, we noticed that some pigs had a higher reprogramming efficiency,"says Li. "So, the second part of our findings, which is significant in biology, is understanding how these differences occur and why."

Li shared that understanding why different pig breeds have varying levels of reprogramming efficiency will directly translate to understanding differences in the effectiveness of iPSC generation between individual humans. In fact, a previous study by Mackey et al., has shown that a person's ethnicity may impact their cell's reprogramming efficiency. So, understanding what mechanisms control cellular reprogramming will be crucial to developing effective protocols of iPSC generation for individualized therapies.

"With this model, we can study musculoskeletal regeneration particularly cartilage regeneration for osteoarthritis patient,"says Li. "But we think the impact is way beyond the application of orthopedics because from now on, anybody on campus who is interested in using the technology we have developed for a minipig model, can reprogram their cells into iPSCs and then these cells and the animal can be used to investigate heart disease, kidney disease, neuronal diseaseor any type of a disease."

Translating this research to improve human health, is deeply important to Li. He has spent much of his career studying novel approaches to regenerate cartilage and bone for orthopedic applications and developing a translational model like this means that science is one step closer to healing more patients using stem cells.

"I feel really touched by the stories people share. You cannot imagine how many emails come in asking me if they can become the first human patient in our future clinical trial,"Li says. "People are in desperate need for something, especially when those people feel the current surgical procedure or intervention is not suitable for them. I have to keep saying, 'wait for another two, three years, maybe we'll be ready for a clinical trial,'but for me, it's time to move on and really do our larger animal studies to fulfill our promise. At least that way, I can fill the gap between the lab and clinical trials as the larger animals must be studied before you go into a clinical trial."

Li's development of a reliable and translational model for the generation of iPSCs in a large animal is critical as it has been a challenge to generate pig iPSCs with efficiency. The reprogramming efficiency of pig cells is relatively low compared to that of human or mouse cells, but large animal studies remain a crucial step in bringing treatments to clinical trials.

Interest in moving these treatments forward has grown and while this study was funded in part by NIH, Li also received support from the Plunkett Family Foundation in Milwaukee through their donation to the UW Stem Cell and Regenerative Medicine Center. After hearing of Li's research, Gwen Plunkett and her daughter Karen visited Li and his lab in 2019 to learn more and were inspired to support research into stem cells for cartilage regeneration.

"Innovation in medicine sparks critical change, for the world and the survival of our species and the Plunkett Family mission is to be a catalyst in stem cell and regenerative medicine research,"says Karen Plunkett. "We supported Jamie Thomson's lab in the early days when federal funding for human stem cell research was restricted. More recently, we continued our commitment to this research by supporting Dr. Wan-Ju Li's stem-cell based approaches for regenerating skeletal tissues, cartilageand bone for orthopedic applications. Additionally, it is personally gratifying to be able to support the SCRMC while my son completes his senior year studying neurobiology at UWMadison.We are happy to be part of the University of Wisconsin family."

Li shared that the donation was profoundly impactful and allowed him to further his goal of using stem cells to help patients struggling with osteoarthritis as well as other joint diseases.

"I want to make sure that our findings in stem cell research can be used to help people,"says Li. "I just feel this internal drive to study this area and I feel good knowing this model carries significant weight in terms of its potential for translational stem cell research and the development of therapeutic treatments."

This research was supported by grants from the National Institutes of Health (R01 AR064803) and the Plunkett Family Foundation. The UW Department of Pathology and Laboratory Medicine and UWCCC (P30 CA014520) and the Small Animal Imaging andRadiotherapy Facility and Flow Cytometry Laboratory, supported by UWCCC (P30 CA014520) also provided facilities and services.

Source: University of Wisconsin-Madison, whichis solely responsible for the information provided, and wholly owns the information. Informa Business Media and all its subsidiaries are not responsiblefor any of the contentcontained in this information asset.

Read the rest here:
Reprogramming pig cells leads way for new regenerative therapies - National Hog Farmer

Skin Stem Cells Comments Off on Reprogramming pig cells leads way for new regenerative therapies – National Hog Farmer | September 27th, 2022

- CRC data on cord lining media for the treatment of diabetic foot ulcers has been accepted at the DFCon, with Dr Wong Keng Lin Francis, CRC's latest KOL, presenting his findings to world leaders in the field of DFU.- Similarly, the results of Corlicyte's Phase 1 study on the treatment of chronic diabetic foot has also been accepted with the presentation being given by Dr Cecilia Low-Wang, the trials Principal Investigator.- DFCon is a global specialist multi-disciplinary congress that attracts specialists in the field of the diabetic foot and is considered the most influential event in the industry. It is co-founded by Dr David Armstrong, a pre-eminent expert in diabetic foot.- Dr Armstrong, who also serves on CRC's scientific advisory board, will be giving the opening address for CRC's breakfast symposium on their lead products Sollagen and Corlicyte.- CorLiCyte is an umbilical cord lining stem cell therapy, for patients suffering with diabetic foot ulcers (DFU), Sollagen is a brand targeting diabetic's skin.- Global diabetes patient population is set to grow from 537 million in 2021 to 783 million in 20451- DFU is a global health emergency that will affect close to 20% of the diabetic population in their lifetime

LOS ANGELES, Sept. 26, 2022 /PRNewswire/ -- CRC is delighted to announce attendance at DFCon, the global specialist multidisciplinary congress focused on the diabetic foot held in late September 2022 in Los Angeles, USA. The meeting is a gathering of a wide range of both generalists and specialists who diagnose and manage diabetic feet, to discuss best practice in diagnostics and interventions for both treatment and amputation prevention. It was co-founded and is co-chaired by Dr David Armstrong, a pre-eminent expert in diabetic foot who also serves on CRC's scientific advisory board.

Dr David Armstrong will be introducing CRC's headline symposium on Saturday morning where Dr Paul Kemp, the inventor of Apligraf and scientific advisory board member, and esteemed researchers Dr Brian Freed and Dr Wong Keng Lin Francis will present an overview of CRC's technology and data.

Furthermore, CRC have two scientific posters approved for presentation at DFCon on the data generated in Corlicyte and Sollagen:

The first poster "Results of the phase 1 open-label safety study of umbilical cord lining (Corlicyte) to heal chronic diabetic foot ulcers" details the Phase I study in Corlicyte and is authored by Cecilia Low Wang and the team from the University of Colorado who conducted the study.

The second poster by Dr Wong from Sengkang General Hospital/Duke NUS is titled "Early evaluation of Sollagen, a topical exosomal skin conditioner derived from Umbilical cord lining cell media, in treatment of persistent chronic DFU" and details the impressive early data generated with Sollagen in chronic diabetic foot ulcers.

Both posters are a testament to the immense potential of Corlicyte and Sollagen for the treatment of diabetic foot ulcer, a huge issue for patients and health care systems alike.

CRC's presence at such a specialized and well-regarded scientific and medical forum reflects the exciting data the company is generating. It is a strong indication of the academic and clinical network that the company is building to deliver products that can make a dramatic difference to patients with a large unmet medical need.

About CellResearch Corporation (CRC)

CellResearch Corporation was founded in 2002 as a contract research provider focusing on skin cells. In 2004, the company made the discovery that the umbilical cord lining of mammals was an abundant source of both mesenchymal and epithelial stem cells. Today, the company owns this technology through a family of patents and holds the rights to commercialize this technology in most major markets globally. While the closure of diabetic foot ulcers is the company's first allogeneic therapy to make it to the end of Phase 1 USFDA clinical trials, CellResearchCorp has a broad therapeutic pipeline at the pre-clinical stage. Further therapies include solid tumor therapy, inflammatory diseases, cardiac muscle repair, Parkinson's Disease, Age-related Macular Degeneration and Diabetes.

CellResearch Consumer Health, a wholly owned subsidiary of CellResearch Corp, is the commercialization vehicle for CALECIMProfessional and the newly launching Sollagen. It produces an innovative range of skincare and haircare products using cord lining stem cell media to power its products. It is used in clinics/hospitals and as part of an at-home anti-aging skincare regime. It is distributed globally through over 600 aesthetic physicians and online via their own website. It has a key distribution partnership with Menarini Group across Southeast Asia.

CellResearch Corp partner, Cordlife offers parents the opportunity to bank their child's umbilical cord tissue alongside their cord blood. Cordlife has what is believed to be the largest licensed bank of umbilical cord tissue globally. As cell therapies move into the clinic, Cordlife will have the ability to expand stem cells from a banked umbilical cord for autologous and donor-related uses.

http://www.cellresearchcorp.com

https://calecimprofessional.com

Business Development and Investor Relations:

Xavier Simpson

+65 8815 6139

xaviersimpson@cellresearchcorp.com

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/cellresearch-corporation-crc-to-present-promising-new-stem-cell-products-for-the-treatment-of-chronic-diabetic-foot-ulcers-at-the-worlds-premier-diabetic-foot-conference-dfcon-in-los-angeles-301632771.html

SOURCE CellResearch Corporation

See the original post here:
CellResearch Corporation (CRC) to present promising new stem cell products for the treatment of chronic diabetic foot ulcers at the world's premier...

Skin Stem Cells Comments Off on CellResearch Corporation (CRC) to present promising new stem cell products for the treatment of chronic diabetic foot ulcers at the world’s premier… | September 27th, 2022

By Dr Chytra V Anand

The fascination with beauty and skincare in India has grown leaps and bounds in recent times, and understandably so, given that the culture of beauty is deeply rooted in the country. The days when beauty was an aspect of social class and the cosmetic treatments and products you access gave away your economic status are long gone, as are the days when cosmetic treatments were considered a girl thing. With cosmetic treatments becoming more accessible and sought-after, the Indian skincare and derma cosmetics market generated an estimated revenue of a whopping USD 188.2 million in 2021. The same is projected to grow at a CAGR of 10.2% between 2021 and 2030.

Today, with changing lifestyles, demographic growth, cutting-edge technology, and improving economic and social conditions thanks to rising per capita and disposable income, India is quickly heading towards becoming a leader in the global cosmetics industry. But for a bit of self-introspection, what are Indian consumers looking for when it comes to cosmetic treatments? What does their consumption tell industry players?

Body hair removal has become one of the most popular cosmetic procedures done across the world today. But compared to shaving, waxing, or using an epilator or a trimmer, laser hair removal is a more permanent hair removal method that has gained immense traction of late. Especially in urban India, laser hair removal has quickly gained popularity, with mothers even bringing their 16-year-olds for Laser hair removal.

In 2021, the global laser hair removal market was valued atUSD 798.6 million, with an estimated CAGR of 18.4% from 2022 to 2030. Given that laser hair removal is a one-time procedure, although one has to sit through multiple sessions, the results, when done by a reliable cosmetic professional, are impressive. The Asia Pacific is projected to be the fastest-growing segment for laser hair removal, especially in countries like India and China.

A cosmetic procedure where a chemical solution is applied to your skin to remove the top layers, Chemical Peels ensure that the skin becomes smoother and clearer, making it radiant. On the other hand, a Medical Clean-up, in the simplest terms, is the procedure of cleaning your skin, ridding impurities like blackheads and white head spots to clear clogged pores. Besides, Medical Clean-ups are also beneficial for people struggling with acne scars, making it a popular procedure that an increasing number of people are choosing. For Chemical Peels, the market size is expected to touch USD 68.81 million between 2021 to 2025, making their popularity surge.

As we grow older, our skin begins to age too, and wrinkles and fine lines begin to appear on our face. Cosmetic procedures like Hydra Facials and skin maintenance with Laser Photofacials are a weekly must-do for 30-45-year-olds to ensure their skin is supple and glowing. Apart from this, the perception of Indian consumers when it comes to cosmetic treatments like Botox and Fillers has begun to change. These are no longer viewed as taboo as people now realise that they give your skin a lift.

Such treatments are also no longer only available for a certain section of society, like the wealthy. Botox and Fillers are now available to everyone, and consumers are looking at them from a skin maintenance standpoint rather than as a luxury, unnecessary treatment. Annually, the Botox segment is registering 20-25% growth in the country proof of evolving consumer preferences and the rising popularity of such treatments. Besides these, derma cosmetics and medical skin care have also gained a fair amount of traction, with skincare aficionados looking for effective and efficient skin care procedures that are non-surgical.

Alongside our skincare, taking care of our mane is equally important. For people struggling with hair fall, flaky and dry scalp, and other issues that affect your hair, stem cell therapy is the answer. Often done annually, stem cell therapy helps rejuvenate your hair cells to retain hair and repair damage. And with the global hair restoration market standing at over USD 4.2 billion in 2020, we can safely say its here to stay.

With consumerism changing face gradually and Indian consumers gaining access to world-class cosmetic treatments that are non-surgical, which still trump surgical procedures, the future of the Indian cosmetic treatments market shines bright. As long as the procedures are done by qualified and experienced professionals and are reliable and effective, the demand for such cosmetic procedures will continue to grow.

(The author isfounder ofKosmoderma Healthcare Pvt. Ltd.Views expressed are personal and do not reflect the official position or policy of the FinancialExpress.com.)

Originally posted here:
A glimpse into Indian consumers expectations for cosmetic treatments and consumption insights - The Financial Express

Skin Stem Cells Comments Off on A glimpse into Indian consumers expectations for cosmetic treatments and consumption insights – The Financial Express | September 27th, 2022

Highlights

Dr Giulia Svizzero, Plastic Surgeon, Tajmeel Clinic, emphasises the importance of patients having realistic expectations to ensure safety and get the best results for their specific needs

Tajmeel is a beauty clinic from Burjeel holdings. We offer an elegant environment supported by the commitment to excellence of our group. We have a team of board-certified specialists with over 15 years of experience in their field. Tajmeels main departments are dental, plastic surgery and dermatology. Tajmeel redefines beauty to give its patients the best results they are looking for.

* Healthy individuals who do not have medical conditions that impair healing.

* Individuals with realistic expectations and positive outlook.

* What do you recommend as the best strategy for youth preservation or anti-aging?

* Sleep is the best anti-aging tool we have, at least 7-8 hours per night.

* Eating a healthy diet. No smoking and no alcohol.

* Healthy dose of omegas in your diet, fish oil supplements of 1,000-2,000mg daily.

* Take vitamin C 1,000mg daily.

* Decrease your sugar intake, as high sugar is very damaging to the skin. Collagen and elastin are particularly susceptible to glycosylation. Damage to these proteins leads to sallow, wrinkled, and sagging skin.

* Consume marine collagen and hyaluronic acid powder.

* Keep yourself well hydrated with alkaline water.

* Exercise for at least 30 minutes a day.

* Try yoga and meditation, and also do what you love to do.

* Daily use of sunblock SPF 50.

* Early use of neurotoxins (Botox or Dysport).

* Non-invasive skin treatments can help maintain the integrity of the skin over time.

* Retin A or vitamin A derivative anti-aging topical therapies.

Dr Giulia Svizzero, Plastic Surgeon

Dr Giulia is a board-certified plastic surgeon with many years of experience. Dr. Giulia received training at several hospitals and specialised clinics in Italy, France and Singapore. She gained broad experience performing high-precision surgeries, microsurgery, plastic surgery, and reconstructive plastic surgery.

Dr Giulias areas of expertise include aesthetic breast surgery (breast lifts, breast reductions, and breast augmentation), liposuction, abdominoplasty, ear reconstruction, oncoplastic breast surgery, and head and neck reconstruction. She is committed to staying current with the latest techniques and procedures in the field of plastic and reconstructive surgery, which is why she attends numerous specialised seminars and international conferences.

Can you prolong the length of time of the need to have a facelift by using new anti-wrinkle alternatives such as injectables?

Genetics play a role in how our face will age to some degree but our lifestyle choices and the way we care for our skin can actually delay the process. Liquid facelift, which uses an assortment of different injectables can help delay the need for surgery. You can go for Botox and fillers to smoothen dynamic wrinkles and restore the volume. Skin boosters can treat the skin superficially using new collagen stimulators or much better stem cells to tighten it to the underlying tissues before its too late, because the extra excess skin is the only thing we cant correct without surgery. However, be careful about not having an over injected look that can result after several liquid facelifts. When that starts happening its better to consider the pony tail lift or the complete face lift.

Body contouring, if done properly, can have wonderful results. What methods do you use for optimal results?

Yes, but again realistic expectations. We dont have a magic wand. We have to draw limits to ensure the safety of the patient and get the best results for the specific surgical indications. It also depends on the starting point, on the deposit of localised fat, and the skin laxity and quality.

With the introduction in the market of new technologies for skin tightening such as J-plasma and Bodytite, I always perform liposculpting with radio frequency that permits us to conduct heat on the skin and shrink it consequently. We can combine the treatment with fat transfer (sometimes enriched with stem cells) to specific areas to correct some depressions and to create more definition in the waistline. And eventually Brazilian butt lift, but again we need to have realistic expectations as not all the reinjected fat will survive long-term, but only about 60 per cent.

We cant ignore that when we have a severe skin laxity and extra excess of skin, we need the body lift or dermolipectomy (cutting the skin) as abdominoplasty, 360 belt abdominoplasty, thighs lift, and arms lift. However, this will result in permanent scarring, even though we position and suture the scar meticulously. Scar healing is a long, complicated and very individual process.

How much of your consultations and treatments are dedicated to assisting individuals who have had less than optimal results from previous procedures?

One of the most requested procedures is liposuction, which may require revisions. This is similar to what happened to the fake large breasts in the past. Breast implants are more popular than ever but now the augmentation has been moving towards a smaller size and natural shape. Patients wearing big and heavy implants are having unpleasant aesthetic consequences such as severe ptosis of the breast that requires a mastopexy or breast lift with implants exchange.

We need to need to be aware of the disaster caused due to the placement of permanent fillers in on the face and body that may lead to serious complications such as allergic reactions, infections, and necrosis (death of skin cells). So to conclude, lets say maybe around 70 per cent of all my procedures.

We see many plastic surgery clinics promoting patient education. How important is this aspect to patients?

It is very important. Patients need to understand perfectly what they will encounter and the realistic results that we can ensure. Besides, all the risks and benefits and the post-surgery or treatment care. The success and good results of plastic surgery is not only in the surgeons hands, but a well done post-operative care will definitely enhance the result.

The Tajmeel Royal Clinic is located on Sheikh Zayed Road, Dubai. For appointments and enquiries call 800 825

Highlights

* Board-certified surgeon with over 15 years of experience

* Member of ISAPS, ASPS, SICPRE

List of treatments

* Breast surgeries (augmentation, reduction, and lifts)

* Abdominoplasty (tummy tuck)

* Body lifts (arms lift, thighs lift, and belt lift)

* Eyebrows and eyelid lifts (ponytail lift)

* Oncoplastic breast surgery

* Head and neck reconstruction

More:
Tajmeel redefines beauty to give its patients the best results - Gulf News

Skin Stem Cells Comments Off on Tajmeel redefines beauty to give its patients the best results – Gulf News | September 27th, 2022

You probably know what hormones are, and you may have at least heard about stem cells, but what is a growth factor? According to Britannica, it is a protein that stimulates growth in specific tissues. There are many types of growth factors, each with the job of repairing certain body parts. Some growth factors include epidermal growth factor (responsible for skin repair), platelet-derived growth factor (responsible for repairing muscles and connective tissues), and nerve growth factor (responsible for stimulating brain cell growth and repair).

According to a 2020 mini-review in Frontiers in Bioengineering and Biotechnology, growth factors are critical for tissue repair and regeneration. In short, growth factors help maintain skin health and heal wounds. As you age and fewer growth factors are available to help with repair and regeneration, injuries take longer to heal. Stem cells factor in because they release growth factors to instigate wound healing, according to a 2010 study in theInternational Journal of Stem Cells.

And the sex hormones estrogen and testosterone play a part in wound healing too. Low estrogen levels or high amounts of testosterone can slow healing. For women, estrogen levels drop after menopause, resulting in slowed healing time (via Wounds).

See original here:
Here Is Why You Heal Slower As You Age - Health Digest

Skin Stem Cells Comments Off on Here Is Why You Heal Slower As You Age – Health Digest | September 27th, 2022

The main patient characteristics are described in Table2. Type of tumor and mobilization were similar between the groups.

Based on AIC minimization, the combined variability structure was selected. The equation of the estimated base model was AP-CD34+=1.63+1.02 (PB-CD34+)+e where e had a zero-mean normal distribution N (0, s2 (k+prediction)2).

The parameter values for intercept, PB-CD34+, k, and were 1.63 (SE=0.72), 0.12 (SE=0.01), 1.76 and 0.49, respectively.

The base model showed a satisfactory goodness-of-fit plot. In the predicted vs the observed scatterplot, the dots were well scattered around the identity line indicating unbiased model predictions. Additionally, the plot of residual values confirmed non-homogeneous variance with greater residual variability for larger predicted values of the AP-CD34+ cell counts. In terms of predictive accuracy, the base model was able to properly predict the percentage of patients achieving both 2 106 and 5 106 AP-CD34+ cells/kg (Fig.2).

AP-CD34+ cluster of differentiation 34+ cells on the first day of apheresis, CI confidence interval.

The base model can be used to characterize the necessary counts of PB-CD34+ to achieve thresholds of 2 106 and 5 106 AP-CD34+ cells/kg (Fig.3).

AP-CD34+ cluster of differentiation 34+ cells on the first day of apheresis, PB-CD34+ peripheral blood-cluster of differentiation 34.

According to the base model, an estimated PB-CD34+ counts of 57.01 (90% CI: 21.76130.76) and 125.24 (90% CI: 72.09330.71) 106/L were necessary to reach thresholds of 2 106 and 5 106 AP-CD34+ cells/kg, respectively, with a probability of 0.90.

Based on AIC minimization, the best model includes the tumor type (neuroblastoma and other) as covariate. The equation of the estimated final model was as follows:

$${{{{{{{mathrm{Neuroblastoma}}}}}}}}:{{{{{{{mathrm{AP}}}}}}}} {mbox{-}} {{{{{{{mathrm{CD}}}}}}}}34^ + = 3.01 + 0.13 times left( {{{{{{{{mathrm{PB}}}}}}}} {mbox{-}} {{{{{{{mathrm{CD}}}}}}}}34^ + } right) + e$$

$${{{{{{{mathrm{Other}}}}}}}};{{{{{{{mathrm{tumor}}}}}}}};{{{{{{{mathrm{types}}}}}}}}:{{{{{{{mathrm{AP}}}}}}}} {mbox{-}} {{{{{{{mathrm{CD}}}}}}}}34^ + = 0.01 + 0.13 times left( {{{{{{{{mathrm{PB}}}}}}}} {mbox{-}} {{{{{{{mathrm{CD}}}}}}}}34^ + } right) + e$$

where e had a zero-mean normal distribution N (0, s2 (k+prediction)2).

The parameter values for intercept-neuroblastoma, intercept-other, PB-CD34+, and were 3.01 (SE=1.10), 0.01 (SE=0.006), 0.13 (SE=0.01), (simeq) 0.00 and 0.54, respectively.

According to the model, the predicted count of AP-CD34+ cells was slightly larger for neuroblastoma tumor types than for the other tumor types. It should be noted that the final model was selected considering the type of tumor as an additional covariate (in addition to PB-CD34+) based on statistical information criterion (AIC), and that the tumor type was correlated with the age of the patients - the patients with Neuroblastoma tumor type, with mean age of 3.7 years (standard deviation, SD=2.1 years), being younger than the others with mean age of 8.9 years (SD=4.8 years). However, the choice of considering tumor type in the final model instead of age was driven by the fact that the fit of the data was improved when tumor type was considered as predictor, as compared to age, which reflected in lower value of the statistical information criterion with tumor type (AIC=288.6) than with age (AIC=310.1).

The final model also showed a good predictive property in terms of goodness-of-fit plot and prediction of the percentages of patients achieving both 2 106 and 5 106 AP-CD34+ cells/kg (Fig.4). The model predicts that a smaller PB-CD34+ cell count was needed to reach 2 106 and 5 106 AP-CD34+ cells/kg with a probability of 0.90 in patients with neuroblastoma tumor type than in those with other tumor types (Fig.5). According to the final model, in patients with neuroblastoma tumor type, the estimated PB-CD34+ counts necessary to reach apheresis thresholds of 2 106 and 5 106 AP-CD34+ cells/kg with a probability of 0.90 were 27.32 (90% CI: 0.1650.51) and 103.20 (90% CI: 56.15165.18) 106/L, respectively. The estimated PB-CD34+ counts necessary to reach thresholds of 2 106 and 5 106 AP-CD34+ cells/kg with a probability of 0.90 in patients with other tumor type were 50.51 (90% CI: 29.3079.12) and 126.39 (90% CI: 77.25198.28) 106/L, respectively.

AP-CD34+ cluster of differentiation 34+ cells on the first day of apheresis, CI confidence interval.

AP-CD34+ cluster of differentiation 34+ cells on the first day of apheresis, PB-CD34+, peripheral blood-cluster of differentiation 34+.

The uncertainty related to these PB-CD34+ estimated values with the final model was slightly less in comparison to the base model probably due to a reduced residual variability.

The physiological process of stem cell mobilization via CXCR4 is comparably the same in subjects of all ages, and when adult data on CXCR4 is extrapolated into children it should closely mirror that seen in children [19]. We complemented our analyses with data from the adult NHL and MM patients who participated in the two plerixafor studies [15, 16], focusing on the first day of apheresis similar to the MOZAIC study. The details of the analyses can be found in theSupplementary section.

More:
Development and validation of a predictive model to guide the use of plerixafor in pediatric population | Bone Marrow Transplantation - Nature.com

Bone Marrow Stem Cells Comments Off on Development and validation of a predictive model to guide the use of plerixafor in pediatric population | Bone Marrow Transplantation – Nature.com | September 27th, 2022

Visiongain has published a new report entitled Mesenchymal Stem Cells Market 2022-2032. It includes profiles of Mesenchymal Stem Cells Market and Forecasts Market Segment by Type {Product (Cell & Cell Lines, Kits Media & Reagents, Others), Services}, Market segment by Source (Bone Marrow, Adipose Tissue, Cord Blood, fallopian Tube, Fetal Liver, Lung, Peripheral Blood, Other Sources), Market Segment by Indication (Bone & Cartilage Repair, cardiovascular Disease, Cancer, GvHD, Inflammatory & Immunological Diseases, Liver Diseases, Other Diseases), Market Segment by Application (Disease Modelling, Drug Discovery & Development, Stem Cell Banking, Tissue Engineering, Toxicology Studies, Other Applications) plus COVID-19 Impact Analysis and Recovery Pattern Analysis (V-shaped, W-shaped, U-shaped, L-shaped), Profiles of Leading Companies, Region and Country.

The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.

Rising Awareness About Therapeutic Potential of Mesenchymal Stem CellsThe mesenchymal stem cell (MSC) market has a huge potential for expansion as it's the most prevalent stem cell type used in regenerative medicine. MSCs are now the most commonly used stem cell type in clinical trials and the most researched stem cell type in the scientific literature. MSC-based therapies are also gaining popularity due to the rapidly aging population and rising prevalence of chronic diseases. Mesenchymal Stem cells play a significant role in effective management of disease and research initiatives in specialized areas such as genomic testing and personalized medicine. As a result of rising awareness of the therapeutic potential of stem cells and the scarcity of effective therapeutic treatments for rare diseases there is rise in investment leading to the growth of the market, however significant operational cost associated with the mesenchymal stem cell expansion and banking is anticipated to hinder the market growth.

Download Exclusive Sample of Report @

Mesenchymal Stem Cells Market Report 2022-2032

How has COVID-19 had a Significant Negative Impact on the Mesenchymal Stem Cells Market?

The biotechnology industry has experienced evolutionary changes with regards to the operational management. Typical biopharmaceutical companies manufacturing products for mesenchymal stem cell development had a better response to staff disruptions and challenges evolving due to COVID-19.

There was an impact on the research & development activities and clinical trials as there were interruptions in the new patient enrolment for the active clinical trial. However, the business focused on inventing new therapies for the treatment of COVID-19 disease. In the past years, MSCs have established itself to be an effective technique to treat pulmonary disease, including COVID-19. MSC derived stem cell therapies have showed the potential for the treatment of the Covid 19 disease. Therefore, an increase in the number of clinical trials using MSCs has been observed. Countries such as the US, the UK, Belgium, France, Spain and Mexico are conducting clinical trials with mesenchymal stem cells to be used in the treatment of COVID-19.

How will this Report Benefit you?

Visiongains 281-page report provides 117 tables and 184 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the mesenchymal stem cells market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Mesenchymal Stem Cells Market. Get financial analysis of the overall market and different segments including type, Source, Indication, Application, and company size and capture higher market share. We believe that there are strong opportunities in this fast-growing mesenchymal stem cells market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the Current Market Drivers?

MSCs in the Development of Engineered Tissues and OrganshMSCs are considered as one of the prominent bio fabrication materials for decades as they are proved safe and effective in treating various injuries and diseases such as bone or cartilage regeneration, stroke & cancer. Bioprinting is a rapidly expanding tissue engineering area with a lot of promise for product customization and addressing the global tissue and organ scarcity, with a global market of $1.82 billion USD predicted by 2022. hMSCs have also been found to be capable of being guided toward hepatocyte differentiation thus indicating huge demand for hMSCs as tissue engineering of organ develops. The requirement for hMSC in engineered tissue and organ applications is, of course, reliant on cell generation, differentiation, and maturation technologies for the parenchymal cells required for organ function and thus it is expected that the increased availability of hMSC sources as a result of manufacturing technology advancements will pave the way for quick improvement and growth of the mesenchymal stem cells market.

Rise in Focus Towards Regenerative Medicine TherapiesMSCs are a good cell source for tissue regeneration because of the following characteristics. MSCs can be sourced from various tissue, including umbilical cord, fetal liver, bone marrow, and synovium. MSCs have the ability to develop into practically any end-stage lineage cell, allowing them to seed specific scaffolds. MSCs are potential immune tolerant agents as they have characteristics such as anti-inflammatory, immunoregulatory & immunosuppressive. Several clinical papers back up MSC-based cell therapy's potential efficacy; while its efficacy is still restricted, the results are encouraging.

MSCs have been investigated and used extensively in regenerative medicine. MSCs have moved closer to therapeutic applications for disease therapy and tissue repair in recent years due to improvements in extraction, culture, and differentiation procedures , therefore future research into better biomaterials and effective inducing factors will help MSCs advance in their regenerative medicine applications.

Get Detailed TOC @

Mesenchymal Stem Cells Market Report 2022-2032

Where are the Market Opportunities?

MSC Therapy to Treat Multiple SclerosisThe therapeutic application of MSCs in treating Multiple Sclerosis has proved to provide huge potential by improving clinical symptoms, thereby stabilizing the disease progression. MSCs have properties such as immunomodulator, tissue-protector and repair promotion has proved MSCs to be an attractive therapy option in the treatment of Multiple Sclerosis as well as in other conditions such as inflammation and tissue injury.

MSCs when administered, combat the inflammation in body and regulate the immune system which will further prevent myelin degradation. Clinical trials demonstrating the application of MSCs in Multiple Sclerosis patients have shown increased energy levels, improved flexibility, strength, and mobility. It has also been observed that if MSCs are administered intravenously may have the ability to halt diseases progression for an extended time duration.

MSCs offer intrinsic benefits over hematopoietic stem cells, that MSCs can differentiate into a cell types, release immunoregulatory molecules and promote release of exosome and growth factors

Competitive LandscapeThe major players operating in the mesenchymal stem cells market are Thermo Fischer Scientific Inc., Merck KGaA (Millipore Sigma), STEMCELL Technologoes Inc., Cytori Therapeutics Inc. (Plus Therapeutics Inc.), Cyagen Biosciences, PromoCell GmbH, Celprogen Inc. Stemedica Cell Technologies Inc., Cell Application Inc., Lonza, Celltex Therapeutics Corporation. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launches.

Recent Developments

Avoid missing out by staying informed order our report now.

To find more Visiongain research reports on the Pharma sector, click on the following links:

Do you have any custom requirements we can help you with?Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help:dev.visavadia@visiongain.com

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent market intelligence providers around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports, which cover 10-year forecasts, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets with a lot of synergies. These markets include automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customised and syndicatedmarket research reportsoffer a bespoke piece of market intelligence customised to your very own business needs.

Contact:Dev VisavadiaPR at Visiongain Reports LimitedTel: + 44 0207 336 6100Email: dev.visavadia@visiongain.com

Read the original here:
Mesenchymal stem cells market is projected to grow at a CAGR of 13.82% by 2032: Visiongain Research Inc - GlobeNewswire

Bone Marrow Stem Cells Comments Off on Mesenchymal stem cells market is projected to grow at a CAGR of 13.82% by 2032: Visiongain Research Inc – GlobeNewswire | September 27th, 2022

REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that data from the companys investigator-sponsored study of JSP191 as a conditioning agent in the treatment of Fanconi Anemia were presented at the annual conference of the Inborn Errors Working Party (IEWP), a research group of the European Society of Blood and Marrow Transplantation, held on September 23-25, 2022, in Paris, France.

The study is a Phase 1/2 clinical trial (NCT04784052) utilizing JSP191 to treat Fanconi Anemia patients in bone marrow failure requiring allogeneic transplant with non-sibling donors. The objective of the study is to develop cell therapy for Fanconi Anemia which enables enhanced donor hematopoietic and immune reconstitution with decreased toxicity by transplanting TCR ab+ T-cell/CD19+ B-cell depleted stem cells from a donor, after using JSP191 as a part of conditioning. Primary outcome measures include the number of patients without treatment-emergent adverse events following the administration of JSP191.

In the data series presented, 100% complete donor chimerism was achieved through six months for the first patient and at one month for the second patient. Neutrophil engraftment was reached on day 11 for both patients and platelet engraftment was achieved on days 9 and 14. JSP191 was cleared by day 9 after dosing and no treatment-related adverse events or toxicities were observed.

Patients affected by Fanconi anemia have increased sensitivity to conventional conditioning regimens and radiation due to innate defects in DNA repair, said Ronald Martell, President, and CEO of Jasper Therapeutics. JSP191 offers a targeted conditioning strategy that eliminates the need for radiation or alkylating agents like busulfan. Initial data from this study suggest that a conditioning regimen that includes JSP191 has the potential to achieve successful donor transplant with no JSP191-related adverse events or toxicities reported to date. The positive update presented gives us increased confidence in JSP191, which has now shown promise as a conditioning agent in four indications including acute myeloid leukemia, myelodysplastic syndromes, severe combined immunodeficiency, and Fanconi anemia. We look forward to continuing support for Stanfords investigation of JSP191 and advancing our broader pipeline for JSP191 to the next phase of development.

The details of the oral presentation are as follows:

Title: JSP 191 clinical trial updateSession Name: Conditioning for HSCT in IEIPresenter: Rajni Agarwal-Hashmi, M.D., Professor of Pediatrics and Stem Cell Transplantation, the Stanford University School of MedicineDate/Time: Saturday, September 24, 2022, 2 pm CESTLocation: The Imagine Institute in Paris, France

About Fanconi AnemiaFanconi Anemia (FA) is a rare but serious blood disorder that prevents the bone marrow from making sufficient new red blood cells. The disorder can also cause the bone marrow to make abnormal blood cells. FA typically presents at birth or early in childhood between five and ten years of age. Ultimately it can lead to serious complications, including bone marrow failure and severe aplastic anemia. Cancers such as AML and MDS are other possible complications. Treatment may include blood transfusions or medicine to create more red blood cells, but a hematopoietic stem cell transplant (HSCT) is the only cure.

About JSP191

JSP191 is a humanized monoclonal antibody in clinical development as a conditioning agent that blocks stem cell factor receptor signaling leading to clearance of hematopoietic stem cells from bone marrow, creating an empty space for donor or genetically modified transplanted stem cells to engraft. To date, JSP191 has been evaluated in more than 100 healthy volunteers and patients. Four clinical trials for acute myeloid leukemia (AML)/ myelodysplastic syndromes (MDS), severe combined immunodeficiency (SCID), sickle cell disease (SCD) and Fanconi anemia are currently ongoing. The Company plans a new study of JSP191 as a second-line therapeutic in lower-risk MDS patients in 2022 as well as to a pivotal study in AML/MDS transplant in early 2023. Enrollment in additional studies are planned in patients with chronic granulomatous disease and GATA2 MDS who are undergoing hematopoietic cell transplantation as well as a study of JSP191 as a chronic therapeutic for low to intermediate risk MDS patients.

About Jasper Therapeutics

Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking programs. JSP191, an anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing hematopoietic cell transplantation. It is designed to enable safer and more effective curative allogeneic hematopoietic cell transplants and gene therapies. In parallel, Jasper Therapeutics is advancing its preclinical mRNA Stem Cell Graft Platform which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases, and autoimmune diseases than is possible today. For more information, please visit us at jaspertherapeutics.com.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as believe, may, will, estimate, continue, anticipate, intend, expect, should, would, plan, predict, potential, seem, seek, future, outlook and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the potential long-term benefits of hematopoietic stem cells (HSC) engraftment following targeted single-agent JSP191 conditioning in the treatment of severe combined immunodeficiency (SCID) and Jaspers ability to potentially deliver a targeted non-genotoxic conditioning agent to patients with SCID. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Jaspers product candidates; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that Jaspers product candidates may not be beneficial to patients or successfully commercialized; patients willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jaspers business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jaspers business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jaspers filings with the SEC. If any of these risks materialize or Jaspers assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jaspers assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contacts:John Mullaly (investors)LifeSci Advisors617-429-3548jmullaly@lifesciadvisors.com

Jeet Mahal (investors)Jasper Therapeutics650-549-1403jmahal@jaspertherapeutics.com

Excerpt from:
Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP...

Bone Marrow Stem Cells Comments Off on Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP… | September 27th, 2022

The family of a Chilliwack man who was diagnosed with leukemia raised more than $10,000 during a golf fundraiser to help fellow patients battling the disease.

Dave Corke was diagnosed with leukemia just two days before Christmas 2020.

Earlier this year, the Corke family hosted a fundraiser golf tournament The Corke Classic to raise money for a B.C. hospital foundation.

He is now a year since his stem cell transplant and doing well, said wife Vanessa Corke. We wanted to help other families battling this cruel disease by organizing a fundraising golf tournament (with) all proceeds benefiting the VGH & UBC Hospital Foundation Leukemia/Bone Marrow Transplant Program of BC.

In April, friends and family came out to the Cheam Mountain Golf Course for the event and raised a total of $11,337.70.

Dave and Vanessa Corke hold a cheque which was presented to Chelsea Wallace, community partnerships officer at VGH Foundation. (Submitted by Vanessa Corke)

Vanessa said the money will significantly impact patients and their families.

She added that she felt it was an important time to share the news of the successful fundraiser as September is Leukemia Awareness Month, plus Daves birthday is Sept. 24.

They plan to make the golf fundraiser an annual event. Next years is set for April 22, 2023.

Back in 2021, the Corke family had financial help while Dave underwent treatment at Vancouver General Hospital.

READ MORE: Maple Ridge woman runs more kms each day to raise funds for Chilliwack friend with leukemia

Friends rallied to raise funds to help pay for hospital appointments, medication and to ease their financial stresses due to Dave being unable to work.

April Migneault was one of those friends who stepped up, doing a month-long fundraiser run. She started out on April 1, 2021 running one kilometre and gradually increased her distance by a kilometre every day, ending with a 30-kilometre run on April 30.

Earlier that same month another friend, Sharon Reeder, organized a golf fundraiser which brought in more than $10,000. And Debbie Channing set up a GoFundMe where more than $15,000 was raised.

Patients who undergo leukemia/bone marrow transplants have their diseased bone marrow destroyed by high-dose chemotherapy and are then transplanted by infusing healthy bone marrow stem cells. Through the course of their treatment, patients need to visit the hospital regularly until they can return back to their community.

Donations received through VGH & UBC Hospital Foundation support temporary relief to patients and families in need by providing them with travel vouchers, grocery cards, medication and accommodation support so they can take the time to heal without worrying about living essentials.

Do you have something else we should report on? Email: jenna.hauck@theprogress.comTwitter: @PhotoJennalism

Like us on Facebook and follow us on Twitter.

Cancerfundraiser

See the original post here:
Chilliwack man, diagnosed with leukemia, and family raise more than $10000 for hospital foundation - Chilliwack Progress

Bone Marrow Stem Cells Comments Off on Chilliwack man, diagnosed with leukemia, and family raise more than $10000 for hospital foundation – Chilliwack Progress | September 27th, 2022

Dr. Zachary Prudowsky has never met the woman whose life he helped save by being a bone marrow donor, but he feels a special connection to her.

Prudowsky, a pediatric hematologist/oncologist, was preparing to move to Houston when the National Marrow Donor Program reached out to him in 2018. The nonprofit, which receives funding from Congress to operate its Be The Match registry of volunteer donors in the U.S., told Prudowsky he was a preferred donor for a woman with leukemia.

It wasnt until one year after his donation that he learned the woman lived in Katy and had her bone marrow transplant at M.D. Anderson Cancer Center.

MORE HOUSTON GIVES: After pandemic isolation, Ronald McDonald House volunteers eager to bring back human touch

Absolute serendipity, said Prudowsky, who is now 33. This saved a Texan, which is really, really cool.

She also sent him a note, saying his donation allowed her to meet her newborn grandchild. She referred to herself as granny, which tugged at Prudowskys heartstrings. That's what he calls his own grandmother.

That child gets to grow up with a grandmother because of Be The Match, he said. Thats where its really special for me.

Donate bone marrow: If you are between the ages of 18 and 40 and meet health guidelines, you can sign up to join the Be The Match Registry at bethematch.org. You can sign up online or find a local Be The Match Registry event.

Make a financial donation: You can also sign up to make one-time or monthly donations to the Be The Match Registry, or arrange your own fundraiser, at bethematch.org.

Prudowsky now serves as an advocate for Be The Match and the NMDP, which oversees a registry that includes more than 39 million potential donors. The NMDP helps facilitate more than 7,500 bone marrow transplants each year, Chief Policy Officer Brian Lindberg said.

Prudowsky and Lindberg are now advocating for Congress to pass H.R. 7770, or the Life-Saving Leave Act. The bill, introduced in May by Democratic Rep. Dean Phillips of Minnesota, would amend the Family Medical Leave Act of 1993 to provide up to 40 hours of unpaid, non-consecutive leave for bone marrow or blood stem cell donors.

The bill essentially seeks to guarantee that a donor wont lose his or her job while taking time off to help save a life, Lindberg said.

The thing that we cant do is promise that person that after theyre done with this process that their job will be waiting for them in the end, he said. Thats what this bill is intended to solve.

Prudowsky enrolled as a donor in 2011, during his first year of medical school in South Carolina. He knew he planned to treat cancer and blood disorders for a career, so he felt it made sense for him to sign up.

He didnt hear anything until 2018, near the end of his residency in Ohio. The NMDPreached out to inform him that he was the preferred donor for the Texas woman. Coincidentally, Prudowsky was preparing to move to Texas for a fellowship at Baylor College of Medicine.

He underwent several tests to confirm he was the best match. Less than three months after the call, he made his donation at the Gulf Coast Regional Blood Center in Houston.

Prudowsky donated via a process called peripheral blood stem cell collection (PBSC). Prior to the donation, donors get five days of injections of a drug called filgrastim to increase the number of blood-forming cells in their bloodstream. Those same blood-forming cells are found in bone marrow. The injections are given in outpatient clinics, and there are many instances where donors can return to work immediately afterward, Lindberg said.

On the day of the donation, blood was taken from Prudowskys arm and routed through a machine that collects those blood-forming cells. The rest of his blood was then returned to him through a needle in his other arm. The whole procedure took roughly four hours.

It was pretty uncomplicated, Prudowsky said. I kind of knew what I was getting myself into, but it was not a difficult process by any means.

Approximately 70 to 80 percent of all marrow donations occur via PBSC, Lindberg said.

The rest occur via traditional bone marrow donation, where a donor is put under anesthesia so a physician can collect cells from their hip. After that procedure, donors may experience soreness for the next few days, Lindberg said.

Weve heard it described many times as the kind of soreness that would be involved if you accidentally bumped into the corner of your dining room table.

The 40 hours outlined in the Life Saving Leave Act could be applied to recovery time, Lindberg said.

Prudowskys decision to be a donor while working as a doctor is not unique; both he and Lindberg said they know of others who work in medicine and are also signed up to be potential donors. But actually being matched can be tricky. Genetics has a lot to do with it: roughly 30 percent of patients have a family member who will be a fully-matched donor; the other 70 percent will need an anonymous donor from a registry.

Even then, the odds of finding a match vary greatly by ethnicity. While 79 percent of white patients will find an anonymous match, that drops to just under 50 percent for Asian and Hispanic patients, and to just 29 percent for Black patients, according to the NMDP.

The NMDPdoes help facilitate bone marrow transplants involving international donors and patients to increase the odds of finding a match, Lindberg said.

MORE HEALTH NEWS: A Katy man opted for surgery to treat prostate cancer, and a novel procedure limited side effects

However, its critical to keep recruiting a diverse pool of potential donors, Lindberg said. The greater the number, the greater the chance a patient will find a match.

Signing up to be a donor is straightforward, Prudowsky said. Anyone who is interested can sign up online on the Be The Match website. Theyll then submit a swab of the inside of their cheek, he said.

But Lindberg and Prudowsky also feel the Life Saving Leave Act could make the decision to be a donor even more straightforward. The NMDP can help donors by covering lost wages, as well as travel costs and other expenses during the process. But it cant guarantee theyll have a job if they take time off to donate.

There is simply no reason for anyone to be at risk of losing their job when it comes to potentially saving a life, Phillips said in a news release announcing the introduction of the bill.

Thirty-eight states already have laws that offer some level of paid or unpaid leave for bone marrow donors, but they vary widely, Lindberg said. Texas, for example, offers up to five days of leave without a reduction in salary, but the law only applies to state employees. The Life Saving Leave Act would create a uniform, federal standard, Lindberg said.

Lindberg is optimistic that the bill will become law. It has bipartisan support among seven cosponsors. Lindberg also said it has little to no economic impact because the leave is unpaid.

In the meantime, Prudowsky hopes more people will sign up for the Be The Match registry. He's seen his own patients learn they had a match for a bone marrow transplant, so he knows what a difference it can make.

"In my time in medicine, one of the most fulfilling things, if not the most fulfilling thing I've ever done, is this," he said. "And I didn't even have to be a doctor to do it."

evan.macdonald@chron.com

Read the rest here:
A Houston doctor who saved a life by donating bone marrow wants to help others do the same. - Houston Chronicle

Bone Marrow Stem Cells Comments Off on A Houston doctor who saved a life by donating bone marrow wants to help others do the same. – Houston Chronicle | September 27th, 2022

--Two-Year Follow-Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients who Underwent the StemSpine Procedure for Treating Chronic Lower Back Pain --

PHOENIX, Sept. 26, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, neurology, and orthopedics, today announced the peer reviewed publication of positive, two-year follow-up data for the Company's StemSpine study, showing significant efficacy of the StemSpine procedure for treating chronic lower back pain without any serious adverse effects reported.

Creative Medical Technology Holdings, Inc. Logo (PRNewsfoto/Creative Medical Technology Hol)

The StemSpine publication demonstrates the clinical use of the patented procedure that utilizes a patient's own bone marrow aspirate for the treatment of chronic lower back pain. There were no safety related concerns at up to two years follow-up. The StemSpine procedure resulted in an efficacy rate of 87% in the treated patients in terms of decreased pain and increased mobility.

"The positive two-year data from our StemSpine study is very encouraging and may help alleviate the current opioid crisis related to prescription medication abuse for chronic lower back pain," said Timothy Warbington, President and CEO of the Company. "To our knowledge, this is the first demonstration of the clinical efficacy of injecting bone marrow aspirate into areas surrounding the disc, which may repair, remodel and improve the blood supply around the disc and lower back area. We believe StemSpine represents an attractive non-surgical option for many of the millions of Americans who suffer from chronic lower back pain and look forward to further translation."

The StemSpine patent also covers the use of off the shelf adult donor stem cells (allogeneic) for this indication.

The publication may be found at http://www.creativemedicaltechnology.com.

Story continues

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a biotechnology company specializing in regenerative medicine in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. For further information about the Company, please visit http://www.creativemedicaltechnology.com.

Forward Looking Statements

This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at http://www.sec.gov.

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-announces-peer-reviewed-publication-of-positive-results-for-stemspine-study-301632695.html

SOURCE Creative Medical Technology Holdings, Inc.

Read the rest here:
Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine Study - Yahoo Finance

Bone Marrow Stem Cells Comments Off on Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine Study – Yahoo Finance | September 27th, 2022

The global stem cell market size is expected to reach USD 19.13 Billion in 2028 at a CAGR of 8.4% during the forecast period, according to the latest report by Reports and Data.

The globalstem cell marketsize is expected to reach USD 19.13 Billion in 2028 at a CAGR of 8.4% during the forecast period, according to the latest report by Reports and Data. Growing adoption of stem cell therapies to treat chronic and rare diseases, rising number of clinical trials for regenerative medicine globally, and rapid progress in stem cell research are key factors expected to drive market revenue growth over the forecast period. In addition, increasing investment by major pharmaceutical and biotechnology companies, advancements in regenerative medicine, and development of advanced gene editing and tissue engineering techniques are also expected to contribute to revenue growth of the market going ahead.

Stem cells are unspecialized cells that have the ability to develop into different types of cells such as liver cells, muscle cells, and brain cells, among others. Stem cells have remarkable ability of self-renewal in undifferentiated state and can differentiate into various cell types with specific functions under appropriate triggers. Stem cells have played a major role in regenerative medicine, with increasing focus on stem cells of human origin such as adult stem cells, somatic stem cells, and embryonic stem cells. These cells can be used to regenerate human cells, organs, and tissues and have the capability to restore normal function after disease or debilitating injury. During embryonic development, stem cells can form cells of all three germ layers mesoderm, endoderm, and ectoderm. They play a crucial role in repair system of body and normal turnover of regenerative organs such as skin and blood, and this has boosted their importance in medical therapies for the treatment of various degenerative illnesses.

Get a sample of the report @https://www.reportsanddata.com/sample-enquiry-form/2981

Increasing investment to accelerate stem cell research, rapid adoption of stem cell therapies for the treatment of chronic and neurodegenerative disorders, and the increasing number of clinical trials across the globe are some key factors expected to drive market growth Our Expert Review

Recent advancements in stem cell biology and research have enhanced the application scope of stem cell therapy in treating diseases wherein currently available medical therapies have failed to cure, prevent progression, or alleviate symptoms. This is also a key factor expected to contribute to revenue growth of the market over the forecast period. However, ethical issues and political controversies, concerns related to immunity, and stringent regulatory policies associated with stem cell research are some key factors expected to restrain market growth to a certain extent over the forecast period.

Some Key Highlights from the Report:

Asia Pacific is expected to lead the market growth over the coming years owing to rapid advancements in the healthcare sector in APAC countries such as India, China, and Japan. North America is anticipated to register the highest market growth over the forecast period attributed to the increasing availability of robust healthcare and clinical settings, legalization of medical marijuana, favorable reimbursement scenario, presence of key market players, and rapid technological advancements in the region.

The growing popularity of over-the-counter medications driving market growth

Growing incidence of acute and chronic diseases and lesser access to advanced medical facilities owing to low disposable income levels are driving the demand for over-the-counter medications. Availability of generic and low-cost alternatives to medical therapies are some other factors playing a major role in driving demand for over-the-counter medications.

Restriction on product launches and R&D activities to hamper the market growth

The imposition of strict government regulations and shortage of funds has put a halt on product launches and R&D activities and is expected to restrain market growth over the forecast period. In addition, the launch of expensive drugs and therapies and increasing regulations regarding safety and approvals are also hampering the market growth.

Competitive Landscape:

The global market comprises various market players operating at regional and global levels. These key players are adopting various strategies such as R&D investments, license agreements, partnerships, mergers and acquisitions, collaborations, and joint ventures to gain a robust footing in the market.

Top Companies Profiled in the Report:

Celgene Corporation, Virgin Health Bank, ReNeuron Group plc, Biovault Family, Mesoblast Ltd, Precious Cells International Ltd, Caladrius, Opexa Therapeutics, Inc., Neuralstem, Inc., and Pluristem.

Stem Cells Market Segmentation:

Product Outlook (Revenue, USD Billion; 2018-2028)

Technology Outlook (Revenue, USD Billion; 2018-2028)

Therapy Outlook (Revenue, USD Billion; 2018-2028)

Application Outlook (Revenue, USD Billion; 2018-2028)

Regional Outlook:

Frequently asked questions addressed in the report:

Thank you for reading our report. For more details please connect with us and our team will ensure the report is customized to meet all the needs of clients. The report also offers a comprehensive regional analysis and specific countries can be included in the report according to the requirements.

Explore Latest Trending Research Reports By Reports and Data:

3D Printing in Healthcare Market, By Technology Type (Material Extrusion, Photopolymerization, Powder Bed Fusion, Material Jetting, Binder Jetting, Sheet Lamination, Directed Energy Deposition), By Application, By End User (Hospitals and Clinics, Pharmaceutical Companies, Research Institutes), and By Region Forecast to 2028

Ambulatory Surgery Center (ASC) MarketAnalysis By Type (Hospital-Based Ambulatory Surgery Centers, Free-Standing Ambulatory Surgery Centers, Others) By Specialty, By Treatment, And By Region Forecasts To 2028

Bioresorbable Coronary Stents MarketBy Product Type (Polymeric, Metallic), By Brand, By Application (Coronary artery disease, Peripheral artery disease), By Absorption Rate, By End User (Hospitals, Surgical Centres, Others) And Region, Forecast 2020 To 2028

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Media ContactCompany Name: Reports and DataContact Person: John WatsonEmail: Send EmailPhone: +1-212-710-1370Address:40 Wall St. 28th floor City: New York CityState: NY 10005Country: United StatesWebsite: https://www.reportsanddata.com/report-detail/stem-cells-market

View post:
Stem Cells Market Size Expected to Reach USD 19.31 Billion by 2028: Increasing Number of Clinical Trials Across the Globe - Digital Journal

IPS Cell Therapy Comments Off on Stem Cells Market Size Expected to Reach USD 19.31 Billion by 2028: Increasing Number of Clinical Trials Across the Globe – Digital Journal | September 27th, 2022

A breed of pigs called Wisconsin Miniature Swine created by a team of UWMadison scientists will help researchers better model and understand human diseases. Photo: Jeff Miller

Cells from miniature pigs are paving the way for improved stem cell therapies.

A team led by University of WisconsinMadison Stem Cell & Regenerative Medicine Center researcher Wan-Ju Li offers an improved way to create a particularly valuable type of stem cell in pigs a cell that could speed the way to treatments that restore damaged tissues for conditions from osteoarthritis to heart disease in human patients.

In a study published in Scientific Reports, Lis team also provides insights into the reprogramming process that turns cells from one part of the body into pluripotent stem cells, a type of building block cell that can transform into any type of tissue. These new insights will help researchers study treatments for a wide range of diseases.

The researchers turned to pigs, a well-established animal model for potential human treatments, because translating research to improve human health is deeply important to Li, a professor of Orthopedics and Rehabilitation and Biomedical Engineering. He has spent much of his career studying cartilage and bone regeneration to develop innovative therapies to help people.

Li and members of his Musculoskeletal Biology and Regenerative Medicine Laboratory obtained skin cells from the ears of three different breeds of miniature pigs Wisconsin miniature swine, Yucatan miniature swine and Gttingen minipigs.

University of WisconsinMadison Stem Cell & Regenerative Medicine Center researcher Wan-Ju Li (left) shows a collagen fiber sample to Gwen Plunkett and Karen Plunkett. Funding from the Plunkett Family Foundation has contributed to research on cartilage repair therapies in UWMadisons Musculoskeletal Research Program.

The researchers reprogrammed the cells to create induced pluripotent stem cells and demonstrated that they have the capacity to become different types of tissue cells. Pluripotent stem cells are the bodys master cells, and they are invaluable to medicine since they can be used for the regeneration or repair of damaged tissues.

Findings of this study suggest that the miniature pig is a promising animal model for pre-clinical research. The team plans to use the established pig model to reproduce their recent findings of cartilage regeneration in rats as reported in Science Advances. Regenerating cartilage in animals even more alike to humans moves science one step closer to helping patients experiencing joint diseases such as osteoarthritis.

In successfully developing induced pluripotent stem cells from three different breeds of minipigs, we learned we can take somatic skin cells from these pigs that we programmed ourselves and then inject them back into the same animal to repair cartilage defects, says Li. Or we can create induced pluripotent stem cells from the skin cell that carried the gene causing cartilage diseases such as chondrodysplasia and put that into the culture dish and use that as a disease model to study disease formation.

Li says the approach can be applied to regenerative therapies targeting any organ or tissue.

The team also found that a particular protein complex involved in managing the way genes are expressed, and tied to cellular growth and survival, could influence how efficiently induced pluripotent stem cells are generated. While we successfully created induced pluripotent stem cells from the three different strains of pig, we noticed that some pigs had a higher reprogramming efficiency, says Li. So, the second part of our findings, which is significant in biology, is understanding how these differences occur and why.

These findings, he says, may directly translate to understanding differences in the effectiveness of induced pluripotent stem cell generation between individual people one study has shown cellular reprogramming efficiency varying by age and ancestry and lead to better tailored therapies.

I want to make sure that our findings in stem cell research can be used to help people, says Li. I just feel this internal drive to study this area and I feel good knowing this model carries significant weight in terms of its potential for translational stem cell research and the development of therapeutic treatments.

Interest in moving these treatments forward has grown, and while the study was funded in part by the National Institutes of Health, Li also received support from the Milwaukee-based Plunkett Family Foundation through their donation to the UW Stem Cell & Regenerative Medicine Center. After hearing of Lis research, Gwen Plunkett and her daughter Karen visited Lis lab in 2019 to learn more. They were inspired to support research into stem cells for cartilage regeneration.

Innovation in medicine sparks critical change, for the world and the survival of our species, and the Plunkett Family mission is to be a catalyst in stem cell and regenerative medicine research, says Karen Plunkett.

The donation was profoundly impactful, says Li, allowed him to further his goal of using stem cells to help patients living with osteoarthritis and other joint diseases many of whom write his lab regularly in hope of finding a clinical trial opportunity.

I have to keep saying, Wait for another two, three years, maybe well be ready for a clinical trial, Li says. But for me, its time to move on and really do our larger animal studies to fulfill our promise. At least that way, I can fill the gap between the lab and clinical trials as the larger animals must be studied before you go into a clinical trial.

This research was supported by grants from the National Institutes of Health (R01 AR064803), the Plunkett Family Foundation and UW Carbon Cancer Center.

See the original post here:
Creating stem cells from minipigs offers promise for improved treatments - University of Wisconsin-Madison

Skin Stem Cells Comments Off on Creating stem cells from minipigs offers promise for improved treatments – University of Wisconsin-Madison | September 19th, 2022

SINGAPORE, Sept. 16, 2022 /PRNewswire/ --CellResearch Corporation, a Singapore-based biopharmaceutical company today announced it has successfully closed the first Phase I study in CorLiCyte, a stem cell therapy derived from umbilical cord lining stem cells, with research partners at the University of Colorado, Anschutz Medical Campus and ClinImmune Cell and Gene Therapy.

CorLiCyte is in development for the treatment of a number of serious conditions, with a first target indication of treating diabetic foot ulcer (DFU). In the study protocol nine patients with chronic DFU were treated with CorLiCyte twice weekly for 8 weeks. None of the patients participating in the study experienced any treatment-related adverse events and all subjects saw a reduction in wound size during the treatment period.

"These results are encouraging and can be used to support further research with CorLiCyte in future studies, with the potential to address unmet medical needs in treatment of patients with chronic DFUs." said Cecilia Low-Wang, the lead investigator at the University of Colorado, Anschutz Medical Campus.

About CorLiCyte

CorLiCyte is a live mesenchymal stem cell therapy derived from human umbilical cord lining stem cells, with a proprietary optimised expression of cytokines, growth and cellular factors for the treatment of a number of serious health conditions. In addition to DFU, CRC is pursuing a range of potential indications at pre-clinical stage such as osteoarthritis, venous leg ulcers, chronic inflammatory and autoimmune conditions.

About CellResearch Corporation

CellResearch Corporation (CRC) was founded in 2002 as a contract research provider focusing on skin cells. In 2004, the company made the discovery that the umbilical cord lining of mammals was an abundant source of both mesenchymal and epithelial stem cells. Today, the company owns this technology through a family of patents and holds the rights to commercialise this technology in most major markets globally.

CellResearch Consumer Health (Formerly known as CALECIM Cosmeceuticals) is a wholly owned subsidiary of CRC and produces an innovative range of skin and hair care products using cord lining stem cell media to power its products. It is used in medical hair and aesthetic clinics for in-office treatments and as part of an at-home anti-aging skincare regime. It is distributed globally through over 600 aesthetic physicians and online via its own website. It has a key distribution partnership with Menarini Group across South East Asia.

CRC partner, Cordlife offers parents the opportunity to bank their child's umbilical cord tissue alongside their cord blood. Cordlife has what is believed to be the largest licensed bank of umbilical cord tissue globally. As cell therapies move into the clinic, Cordlife will have the ability to expand stem cells from a banked umbilical cord for autologous and donor-related uses.

Contact:

Business Development and Investor Relations:Xavier SimpsonTel: +65 8815 6139Email: [emailprotected]

http://www.cellresearchcorp.com http://www.calecimprofessional.com

SOURCE CellResearch Corporation

Read the original:
CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte - PR Newswire

Skin Stem Cells Comments Off on CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte – PR Newswire | September 19th, 2022

An Israeli biotech company that recently created mouse embryos using stem cells, hasannounced plans to make human embryos to harvest tissue for organ transplants and anti-aging procedures. But an ethical scientist and stem cell expert with the Charlotte Lozier Institute told CBN News that these strides in stem cell research are a "real call for concern".

Renewal Bio is pursuing advances in stem-cell technology and artificial womb development with the help of Jacob Hanna, a biologist at the Weizmann Institute of Science in Rehovot.

In a peer-reviewed scientific journal, Cell, Hanna explained that without the use of sperm, egg, or fertilization, stem cells placed in a Petri dish spontaneously joined together, outside of the womb, and assembled embryos with beating hearts, intestinal tracts, and brains.

"Remarkably, we show that embryonic stem cells generate whole synthetic embryos, meaning this includes the placenta and yolk sac surrounding the embryo," Hanna said. "We are truly excited about this work and its implications."

Hanna noted that the synthetic embryos were not "real" embryos and did not have the potential to develop into live animals. But that is partly because they don't have the technology, right now, to do so. He did admit that the synthetic mouse embryos are "95% similar to normal mouse embryos."

"My contention would be the technique to create them may be synthetic, but if you have something growing [that has]a beating heart and a nervous system and limbs and digits and other organs that look exactly like the organism you would take out of the womb, its an embryo," Dr. David Prentice, Ph.D. from the Charlotte Lozier Institute told CBN News.

Prentice is the vice president and research director at the Charlotte Lozier Institute and was a founding advisory board member for the Midwest Stem Cell Therapy Center, a unique comprehensive stem cell center in Kansas that he was instrumental in creating.

He told CBN News that using the term synthetic to describe the embryos is misleading.

"It's being disingenuous to make us think that these are not actual organisms," Prentice explained.

"They're coming up with new and different ways to make an embryo is the bottom line," he noted. "And by calling it synthetic, you might say we are lulled into a false sense of security that 'oh there not experimenting on embryos [and]we don't have any problems with them doing this with mice.' But as they've said in their papers they also want to do this with humans."

And Prentice is right about why the firm wants to advance its research.

Hanna admits to taking his "ground-breaking" technology to the next level and creating human embryos. The purpose is to harvest tissue to be used in transplant treatments meant to lengthen a person's life and health.

He's behind Renewal Bio, a startup to make "humanity younger and healthier".

"The vision of the company is 'can we use these organized embryo entities that have early organs to get cells that can be used for transplantation?' We view it as perhaps a universal starting point," Hanna said.

CBN News reached out to Renewal Bio for comment and CEO Omri Amirav-Drory, Ph.D. said they were "not really ready to speak too much about the company."

Hanna told MIT Technology Review they plan to grow human embryos that are the equivalent of a 40 to 50-day-old pregnancy or about two months old. It is an age Hanna considers to be "the best entity to make organs and proper tissue."

Those embryonic blood cells would then be collected, multiplied, and transferred to an individual to help with "infertility, genetic diseases, and longevity", according to the company's website.

"There's a real call for concern here that whether they are making these the old fashion way with an egg and a sperm or they're making it by mixing stem cells together," Lozier explained. "You're still talking about instrumental use of a human being to harvest their spare parts."

Other field experts contend that Hanna's experiments are a step too far and not necessary.

"It's absolutely not necessary, so why would you do it?" Nicolas Rivron, a stem-cell scientist at the Institute of Molecular Biotechnology in Vienna said. He argues that scientists should only create "the minimal embryonic structure necessary" to yield cells of interest.

Prentice pointed out to CBN News that there are more ethical ways to get the same kind of cells.

"Something may be constructed or manufactured ethically and have an ethical source...and you could feel very good about your research because you haven't crossed an ethical line until somebody says 'well let's use it this way'," he explained.

In his next set of experiments, Hanna plans to use his own blood or skin cells and those of his team as the starting point for human embryos.

"It does raise a problem for the stem cell field in general and maybe scientists need to ask that question 'should I do this experiment?' rather than 'can I do this experiment?'," Prentice said.

***Please sign up forCBN Newslettersand download theCBN News appto ensure you keep receiving the latest news from a distinctly Christian perspective.***

Continue reading here:
Israeli Biotech Firm Plans to Create Human Embryos to Harvest Organs, Field Experts Say There are Ethical Concerns - CBN.com

Skin Stem Cells Comments Off on Israeli Biotech Firm Plans to Create Human Embryos to Harvest Organs, Field Experts Say There are Ethical Concerns – CBN.com | September 19th, 2022

There are so many ways to ingest and inhale cannabis for better health, but we tend to overlook the ways cannabis can help us from the outside, too. Cannabis plants contain a bevy of compounds in addition to THC and CBD that benefit the body, such as antioxidants, inflammation fighters, and fatty acids.

The topical application of cannabis or hemp allows us a way to absorb cannabinoids, target specific areas, or take care of the bodys largest organthe skinfor everything from scalp dandruff to sun protection. And with the seasons changing from summer to fall, theres no better time to stock up on ways to maintain your skin barrier before the temperatures really drop.

Check out these CBD and hemp skincare picks for daily use, fun in the sun, and giving your body some much-needed TLC.

Derma-Es Skin De-Stress Calming CBD Cleanser is infused with CBD oil and other soothing ingredients such as aloe and hemp seed oil to gently [lift] away impurities, leaving the skin feeling ultra-moisturized, calm and stress-free. Use it as you would any face cleanser: lather it with water over your face and neck for 60 seconds, rinse, and pat dry.

Product can be found on the Derma-E website and beauty sites such as Ulta.

Flora + Bast has released its Age Adapting Facial Serum, infused with 750mg of CBD, 100mg CBC, 50mg CBG, and 2% hemp seed oil. This luxurious serum claims to help reduce redness, blemishes, and correct other skin imbalances. Rich in phytocannabinoids, Flora + Bast says the serum is designed so skin can be brought to a state of equilibrium where it can repair itself naturally, allowing for optimal skin aging.

This product is the perfect addition to a face routine that needs a little more moisture due to brisk weather.

Product can be found on the Flora + Bast website, and the 357mg CBD version is available on beauty sites such as Sephora.

Primas indulgent broad-spectrum face cream, The Afterglow Deeply Restorative Cream, boasts 500mg of CBD in addition to hyaluronic acid and vegan collagen.

Prima writes that their cream is clinically proven to combat age-inducing stressors, reduce the appearance of redness and discoloration, and increase elasticity for healthy, plump, radiant skin while being hydrating and moisturizing. Packed with antioxidants as well, this cream is more like splendor in a bottle.

This product can be found on the Prima website and beauty sites such as Sephora.

Cannuka is known for their CBD and manuka honey-infused skincare products, and their CBD Calming Eye Balm is the perfect choice for nurturing the delicate skin around your eyes.

Containing 15mg of CBD isolate, the eye balm works to moisturize, protect and refresh your skin while waving goodbye to dark circles. Cannuka writes that the balm is cool to the touch and warms upon contact with your skin and that the balm can be used twice daily.

This product can be found on the Cannuka website and beauty sites such as Ulta.

When taking care of the skin on your face, be sure not to overlook your lips. NYXs Bare With Me Cannabis Sativa Seed Oil Lip Conditioner combines hydration with shine for a soothing lip fix.

NYX says its hemp-infused lip conditioner is ideal for a parched pout and that the silky formula slips on smoothly and glosses lips with a clear shine thats oh so glowy.

This product can be found on the NYX website and beauty sites such as Ulta.

JSNs De-Stress Hemp Seed Oil Body Wash is the perfect way to get an all-over hemp-infused clean. Hemp seed oil, aloe, oatmeal, and lavender come together for a skin-nurturing combination in this body wash.

JSN writes that their body wash helps to balance your dry, stressed out skin for a relaxing, healthy feeling clean.

This product can be found on the JSN website using their store selector.

Exfoliation is one of the cornerstones of luminous skin. The Pink Pomelo & Himalayan Sea Salt Herbal Body Salt Scrub from Hempz is enriched with hemp seed oil and formulated to help reverse aging damage and leave skin soft.

The scrub is microbead free, so you can rest easy knowing no plastics are being wasted, and the lovely citrus scent will leave skin smelling fresh.

This product can be found on the Hempz website and beauty sites such as Ulta.

Related

6 cannabis strains for people who love citrus terpenes

Shaving can cause inflammation and irritation, so using a cannabis-infused product makes sense to help manage some of those negative effects. Andalous CannaCell Botanical Shave Cream has hemp seed oil and hemp cell culture extract, in addition to ingredients such as aloe, rosemary, and lemon balm.

Andalou writes that this skin soothing shave cream with vegan probiotics, CannaCell super antioxidants, nourishing organic hemp seed oil, and hydrating aloe vera provides effortless glide against nicks, cuts, and irritation, as the semitransparent cream allows for easy navigation.

This product can be found on the Andalou website and in select stores.

Packed with 300mg of CBD isolate and hemp seed oil, the Unicorn Soothe & Glow Whipped Body Butter by Truly is a whipped rainbow of hydration.

Truly says their formula helps calm skin inflammation while reducing redness and promoting glowing, naturally healthy skin. Combined with its sweet fruity scent and explosion of colors, its hard to resist.

This product can be found on the Truly website and on beauty sites such as Ulta.

Skincare is not complete with sun protection. Andalous CannaCell Sun Buddy SPF 30 is a facial lotion with SPF 30 and hemp seed oil and vegan hemp stem cells. The sheer sunscreen is gentle on all skin types and packed with pure plant essential oils.

Dont forget to wear sunscreen every day, not just in the heat of summer.

This product can be found on the Andalou website and on beauty sites such as Ulta.

Dont stop at your face. Sunscreen is important for the whole body. This Hemp SPF 50 Sunscreen Lotion from Uncle Bud helps to prevent sunburn while also moisturizing the skin with a powerful blend of antioxidants, vitamins, and hemp seed oil.

Product can be found on the Uncle Buds website and at select stores such as Target.

Uncle Buds CBD Sunburn Gel with Aloe is the perfect remedy for after-sun woes if you come away burnt. This soothing gel has 120mg of CBD and cooling aloe to nurture skin thats been left red hot.

Product can be found on Uncle Buds website and at select stores such as GNC.

Briogeos luxurious CBD + Arnica Flower Soothing Skin & Scalp Oil features 100mg of broad-spectrum CBD, hemp seed oil, and other nurturing ingredients (such as arnica flower and jojoba seed oil) to bring your scalp back to life.

The phytoactive formula is a omega-rich but light. Simply rub it into your scalp as instructed and leave it on overnight to harness the benefits.

This product can be found on the Briogeo website and on beauty sites such as Sephora.

If your skin has ink then that ink is a part of your skin, and it deserves care too. INKEEZEs hemp tattoo ointment contains 1000mg of CBD and can be used as a lubricant during the tattoo process and as aftercare by providing healing support. Infused with essential oils, the ointment was developed by a team of tattooers and skin care specialists.

This product can be found on the INKEEZE website and many online tattoo supply shops.

The Body Shops Hemp Foot Protector is perfect for dry feet that need a little love. Combining hemp seed oil with cocoa butter, the cream will help soften rough heels and moisturize tired feet that have been in sandals all summer.

The Body Shop writes that the cream provides blissful moisture for your hard-working feet. It helps to soothe and soften ultra-dry feet with 24 hours of heavy-duty hydration.

This product can be found on The Body Shops website and in their brick-and-mortar stores.

Rae Lland

Rae Lland is a freelance writer, journalist, and former editor for Weedist and The Leaf Online. With a focus on culture, music, health, and wellness, in addition to her work for Leafly, she has also been featured in numerous online cannabis publications as well as print editions of Cannabis Now Magazine. Follow her on Instagram @rae.lland

By submitting this form, you will be subscribed to news and promotional emails from Leafly and you agree to Leafly's Terms of Service and Privacy Policy. You can unsubscribe from Leafly email messages anytime.

View original post here:
The best CBD and hemp products for pampering your skin this fall - Leafly

Skin Stem Cells Comments Off on The best CBD and hemp products for pampering your skin this fall – Leafly | September 19th, 2022

Depending on whats being carried and how much they can pay, the patient or patients involved will choose either a hand-carry service, a commercial carrier such as DHL or FedEx, or something in between, such as the combination of commercial flights and local couriers that Loewen relied on during the pandemic. The cost of transporting my eggs with FlyVet Europa was 1,300 euros, or about $1,400 at the time. That includes the price of two one-way tickets for Paolo and the egg suitcase, and a few incidental expenses. (When I told Monaco how many eggs were traveling, he quipped, Uno squadro di calcio!a soccer team.)

CryoStork, the division of Cryoport devoted to the fertility sector, offers all three tiers of servicecommercial carriers for something that can be easily replaced (sperm, in other words), a middle-tier service using local couriers and air freight, and a door-to-door hand-carry servicefor prices ranging from a few hundred dollars to as much as $7,000 or $8,000 for an international hand-carry trip.

Ultimately, the pandemic boosted business for Loewen. Today, he and a team of eight colleagues, half employees and half working on a per-shipment basis, handle around 30 to 40 IVF-related shipments each month. Similarly, when the war in Ukraine began, Loewen and other colleagues received frantic requests from clients desperate to move their biomaterials out of the capital, Kiev, where most of the countrys IVF clinics and surrogacy agencies are based, and business shifted to nearby Georgia. But by September, Loewen was planning to once again deliver biomaterials to Ukraine. People want to have babiesconflict or not, he says.

What does it take to be a tissue courier, and how does one get into the field? Everyone I spoke to said that to succeed, you must love traveling, have a calm personality (in case, as happened to Loewen, youre ever surrounded by a knot of armed Belarusian soldiers at the airport and accused of trafficking human organs), and be adept at problem-solving.

Loewen looks for people with experience in the travel sector, who can navigate new cities and wont be rattled by a flight cancellation or a grumpy customs official. Mark Sawicki of Cryoport has several former pilots now working as couriers; their security clearances enable them to move through airports more easily than civilians.

Nicole Dorman, 43, has always loved children; she jokes that her current job as a courier is babysitting. She has three kids, aged 14 to 22, and has been a teachers aide and a school crossing guard, following four years in the US Army. When shes home for a week or two at a time with her kids in between gigs, she also makes deliveries for DoorDash in Clarksville, Tennessee.

WENN RIGHTS LTD / ALAMY STOCK PHOTO

Dorman had begun by transporting stem cells for a Frankfurt-based courier service. When she was looking for work in November of 2020, she emailed a half-dozen IVF courier companies and heard back from Loewen within 15 minutes. She has been working for him ever since, and also does US shipments for the Ukrainian company ARK Cryo, as well as EmbryoPort, a UK-based firm.

Dorman is on the road roughly 70% of each month; when we spoke in mid-May, she was preparing for a weeklong trip beginning with a pickup in Indianapolis, a drop-off in Bratislava, a train ride from there to Prague for another pickup, and then a flight to Greece. Like all couriers whove been working for any length of time, she has frequent flier status. In the 18 months since she started, she has transported more than 90 shipments. Now I can pretty much do it in my sleep, she says.

See the article here:
I took an international trip with my frozen eggs to learn about the fertility industry - MIT Technology Review

Skin Stem Cells Comments Off on I took an international trip with my frozen eggs to learn about the fertility industry – MIT Technology Review | September 19th, 2022

PARIS Barbra Streisand loved her dog Samantha, aka Sammy. The white and fluffy purebred Coton of Tulear was even present on the steps of the Elyse Palace, the French Presidents official residence, when Streisand received the Legion of Honor in 2007.

As the singer and actress explained inThe New York Times in 2018, she loved Sammy so much that, unable to bring herself to see her pass away, she had the dog cloned by a Texas firm for the modest sum of 50,000 dollars just before she died in 2017, at the age of 14. And that's how Barbra Streisand became the happy owner of Miss Violet and Miss Scarlet, two puppies who are the spitting image of the deceased Samantha.

This may sound like a joke, but there is one deeply disturbing fact that Harvard Medical School genetics professor David A. Sinclair points out in his book Why We Age And Why We Dont Have To. It is that the cloning of an old dog has led to two young puppies.

This proves that DNA ours as well as that of Sammy has everything it takes to restore lost youth. This is a property that could be used to "reverse" aging without having to go through the problematic stage of cloning.

The idea rests on identifying the "reset" button of the organism. And aging specialists all have the same piece of good news to announce: this button has been found.

Its name sounds like a Japanese techno-thriller title: "The Yamanaka factors". But Shinya Yamanaka is not a fictional character. He is a scientist specialized in stem cell research who received the 2012 Nobel Prize in Medicine.

If all this sound a bit too science-fictional, you should know that the U.S. biotech company Altos Labs, which was just founded early this year, received a check of three billion dollars from billionaires Yuri Milner and Jeff Bezos. Not bad for a start-up. But this is a start-up with a very promising technology cellular reprogramming, which is nothing more than the name given by biologists to the famous "reset" button.

In 2006-2007, Yamanaka announced to the scientific community that he had discovered a combination of four genes Oct4, Klf4, Sox2 and c-Myc which, when injected into a cell, induces it to go from being a differentiated cell (nerve, blood, and so on) to being a pluripotent stem cell, i.e., one that can subsequently redevelop into any cell type.

It didn't take long for Yamanaka's colleagues to take advantage of his amazing discovery. In 2011, French researcher Jean-Marc Lematre, who worked at the Institute of Functional Genomics at the University of Montpellier (which never received the same financial support as American biotech company Altos Labs!) was the first to experimentally prove, on human tissues, that cellular aging was a reversible process. He and his team succeeded in transforming aging or senescent human skin cells back into young skin cells.

The process has since been improved, since it is no longer necessary to go through the stage of pluripotent cells which can degenerate into cancerous cells to reverse cellular aging. Interrupting the process before reaching this stage is enough to start the series of gene reactions that counter cellular aging.

But that's not all. Since Lematre's pioneering work, biologists from both sides of the Atlantic have shown that what was possible at the level of the cell is also possible at the level of the organism as a whole. As is often the case, they used mice as guinea pigs. At the end of 2016, in a famous study published by the "Cell" magazine, a professor at the Salk Institute (San Diego, California) Juan Carlos Izpisua Belmonte revealed the more than promising results recorded on genetically modified rodents.

The rodents' genome had been enriched with the Yamanaka factors as well as a small piece of additional genetic code, corresponding to a sort of on-off switch. Controlling the activation of the four genes, this "promoter" was itself activated only if the mouse ingested an antibiotic the doxycycline to be precise.

By prescribing this molecule (and thus activating the Yamanaka factors) two days a week throughout the life of the mice, Belmonte and his team increased their lifespan by 40%. "Aging is no longer a unidirectional process, as we thought. We can slow it down and even reverse it," he announced triumphantly. In a very similar experiment, Jean-Marc Lematre has obtained a more modest lengthening, of 15%, but thanks to a single dose of doxycycline. And above all, insists the French researcher, this "extra" lifespan proved to be free of all age-related diseases: osteoporosis, arthritis, pulmonary or renal fibrosis, etc.

The genetic modification of mice is common practice in labs. But should we do the same with humans to get the same result? There was public outcry in 2018 when Chinese researcher He Jiankui gave birth to twins with tampered genomes the first genetically modified children in history with the objective of giving them resistance to HIV.

How we view "GMO babies" may change over the next few decades. But whether it changes or not, it will not be necessary to go that far to do cell reprogramming in humans. A simple vaccine will probably do the trick.

The Covid-19 pandemic made the public aware that a vaccine whether RNA or DNA could be used as a vector to introduce genetic material into the human body. BioNTech's and Moderna's messenger RNA vaccines do this, but many other "viral vectors" exist, such as adeno-associated viruses (AAVs), small, non-pathogenic DNA viruses commonly used in molecular biology to carry one or more "genes of interest. On paper, there is nothing to prevent these genes of interest from being precisely those highlighted by Yamanaka.

And this is what our near future could look like. Around the age of 30, when we are alas, only temporarily! at the peak of our mental and physical fitness, we would receive one or more injections of this viral vector responsible for carrying Yamanaka's factors into us. Nothing would change in our body yet, as the Yamanaka factors have been programmed to remain silent until activated by the promoter. So we would continue to age normally. The passing of the years would no longer be irreparable!

Indeed, as soon as we would start to feel their first undesirable effects, let's say in our mid-forties, we would be prescribed a month's treatment with doxycycline. And then but only then would the youth therapy kick in. White hair disappearing, wounds healing faster, wrinkles fading, organs regenerating, glasses becoming useless... "Like Benjamin Button," writes David Sinclair, "you would experience the sensations of a 35-year-old. Then 30. Then 25. But unlike Benjamin Button, you would not go beyond that limit, because the statute of limitations would be interrupted... You would be about two decades younger biologically, physically and mentally, without having lost any of your knowledge, wisdom or memories."

Of course, such a possibility, if it becomes a reality and especially if it becomes widespread, will revolutionize large parts of society and will not be without its own tricky problems for a resource-limited planet. But who among us, once we reach a certain age, wouldn't dream of regaining our lost youth, while retaining the "benefits of experience"?

From Your Site Articles

Related Articles Around the Web

See the original post here:
Benjamin Button For Real? Scientists Are Close To Cracking The Code To Reverse Aging - Worldcrunch

Skin Stem Cells Comments Off on Benjamin Button For Real? Scientists Are Close To Cracking The Code To Reverse Aging – Worldcrunch | September 19th, 2022